Aviex Technologies LLC

Technology Advantages

Mimicry of a true pathogenic challenge that results in a more complete and effective immune response
Oral and/or multi-modality vaccine administration
Attentuated Salmonella engineered to eliminate sepsis-like symptoms
Prior clinical experience and human safety demonstrated from a Phase I trial in cancer patients
High product yields and cost-effective manufacturing

Technology

Aviex uses a novel patented vaccine platform delivery technology based on live attenuated Salmonella bacteria that has previously proven safe for use in humans and animals. The bacteria are engineered to express target antigens and deliver them to the intestinal mucosa, following oral and/or multi modality administration. In the intestines, the bacteria are able to persist for days to weeks, during which time they continuously produce antigens thereby leading to a potent immune response.

Live attenuated Salmonella-based Vaccines with Simple Production Scheme

Aviex Technologies LLC was founded to develop a novel vaccine platform delivery technology for infectious diseases.

Technology

Aviex Technologies LLC was founded
to develop a novel vaccine platform delivery technology for infectious diseases.